PLEASANTON, CA--(Marketwire - February 04, 2010) -
Arcxis Biotechnologies, a privately held
biomedical device firm, announced that it has entered into an agreement to
further expand its collaboration with IQT, the independent strategic
investment firm that identifies innovative technology solutions to support
the missions of the U.S. Intelligence Community. This investment is linked
to Arcxis' November 2009 funding round led by Claremont Creek Ventures and
Kaiser Permanente Ventures and supports Arcxis' continued development and
"Arcxis Biotechnologies' new fully automated platform, now in prototype
phase, ensures extremely fast and reproducible results, even in the hands
of inexperienced users. This serves not only to reduce experimental errors
commonly encountered with manual techniques, but improves the quantity and
quality of the sample -- a key component to results accuracy," said
Christine Meda, CEO and President. "By efficiently extracting, isolating,
and purifying RNA and DNA from blood, plasma, and environmental samples,
our technology will save time and laboratory resources."
"Arcxis continues to deliver impressive technology capabilities," says
William Strecker, Executive Vice President of Architecture and Engineering
at IQT. "Arcxis' nucleic acid sample preparation and molecular diagnostic
product platforms will be an invaluable technology solution to the public
and private sectors."
Arcxis launched its first products in October 2009, the ArcPure™ sample
preparation kits, which are available for sale on the Arcxis website. The
company will launch its fully automated RNA and DNA sample preparation
device, Xisyl™, to the clinical diagnostic marketplace later this year.
This system will eliminate time consuming steps in manual sample
preparation, as well as provide users a greater volume of purified starting
material for demanding analyses such as organism detection, genotyping,
gene expression and PCR. While the device is designed for efficient nucleic
acid extraction and purification from blood and plasma, its capabilities
make it ideal for preparation of environmental samples. Arcxis has
developed a complementary probe technology, Tentacle Probes®, for
creation of highly sensitive and specific assays.
About Arcxis Biotechnologies
Arcxis Biotechnologies, headquartered in Pleasanton, California, is a
venture backed company formed to develop disruptive technologies for
superior sample processing and pathogen detection accuracy. The company is
developing the Xisyl™ workstation, a nucleic acid sample preparation
platform, and the BioPhalanx™ analysis workstation, a fully automated
sample-to-result system for dramatically improved workflows in the clinical
laboratory and other environments. For additional information, please
visit the company's website (www.arcxis.com) or call (925) 621-7911.
IQT is the strategic, not-for-profit investment firm that works to
identify, adapt, and deliver innovative technology solutions to support the
missions of the U.S. Intelligence Community. Launched by the CIA in 1999 as
a private, independent organization, IQT's mission is to identify and
partner with companies developing cutting-edge technologies that serve the
national security interests of the United States. Working from an evolving
strategic blueprint defining the Intelligence Community's critical
technology needs, IQT engages with entrepreneurs, growth companies,
researchers, and investors to deliver technologies that provide superior
capabilities for the CIA and the larger Intelligence Community. IQT
concentrates on several broad commercial technology areas, including
physical and biological technologies; security; and software and
infrastructure. To date, IQT has engaged with more than 175 companies and
delivered more than 260 technology solutions to the Intelligence Community.
To learn more about IQT, visit www.iqt.org.